Navigation Links
Watson Confirms Amphastar Patent Lawsuit
Date:9/22/2011

tate-of-the-art, aseptic, cGMP compliant facilities develop, manufacture, and market innovative proprietary and generic products using new technologies and delivery systems.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial damages; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended June 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

LOVENOX® is a registered trademark of Sanofi-aventis U.S. LLC.CONTACTS:Investors:Patty Eisenhaur(862) 261-8141Media:Cha
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... March 6, 2015 Ultra Clean ... Intuitive Surgical, the manufacturer of da Vinci® ... Cleaning System. This approval reflects the unit,s ability ... currently in place for the sterile processing industry. ... reprocessing robotic surgical instruments for re-use. ...
(Date:3/6/2015)... 2015  The German Court of Appeal has ruled that ... regimen patent for Alimta® (pemetrexed disodium) would not be infringed ... salt form of pemetrexed in Germany ... The German Court ruled in favor of the generic ... Actavis. This decision vacated the prior decision of the Regional ...
(Date:3/6/2015)... , Alemania, 6 de marzo de 2015 /PRNewswire/ ... soluciones de gestión empresarial de imagen médica, fortalece ... el nombramiento de Randolph Sternberg como ... como director de operaciones. Logo ... Sternberg será responsable de las ventas y ...
Breaking Medicine Technology:Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications 2German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit 2German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit 3TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3
... New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows ... and Pulmonary,Embolism Compared with Enoxaparin with Similarly ... - Late-breaking Phase III clinical trial,data presented ... Thrombosis,and Haemostasis (ISTH) Congress demonstrate that once-daily,rivaroxaban ...
... Massachusetts, July 08, 2007 /PRNewswire/ -- , ... to Urgently,Implement Hospital-Wide Strategies to Optimize VTE ... Provide Appropriate,prophylaxis to Prevent VTE , Venous ... and most of these at-risk patients are ...
Cached Medicine Technology:Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 2International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 3International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 4
(Date:3/6/2015)... (PRWEB) March 06, 2015 As the ... healthcare services programs, the organization has hired two new ... Ph.D. They will report to Grace Pavlath, Ph.D, ... President and Scientific Program Director, and together will lead ... to treatments and cures for various types of neuromuscular ...
(Date:3/6/2015)... 2015 “On Tap” takes the audience on ... stage, to the silver screen and to modern day rhythm ... numbers and their famous eye-high kicks! Producers, directors and choreographers ... of tap dancing in this robust show, showcasing one of ... United States. , “On Tap” is proud to host ...
(Date:3/6/2015)... 06, 2015 US Sports Football Camps ... camps – two non-contact specialty camps and one contact ... Perfect Performance Training, located at Bowie State University and ... position specific skills, speed and strength of football athletes. ... University with Marvin Graves, former quarterback in the Canadian ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 At ... company, announced today the launch of its powerful, ... on healthy and sustainable products at any retailer ... is exhibiting at Expo West Booth 6054. ... by gluten-free, Kosher, non-GMO, organic, Paleo, and vegan, ...
(Date:3/6/2015)... March 06, 2015 Johnson & Johnson ... verdict on March 5, 2015 in Superior Court in ... court documents, a jury of 12 awarded Mrs. Perry ... being implanted with an Ethicon TVT Abbrevo plastic sling ... and three women also awarded $5 million in punitive ...
Breaking Medicine News(10 mins):Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3
... , TUESDAY, Feb. 8 (HealthDay News) -- Heavy drinking ... and is associated with long-term alcohol-related problems, researchers warn. ... drinking among older teens not only prevents immediate harm, ... the study authors pointed out. The researchers reviewed ...
... slightly higher in the offspring of male cancer survivors ... cancer, according to a study published online February 8th ... The increasing number of male cancer survivors ... their offspring. Although previous studies on children conceived naturally ...
... -- Researchers at the University at Buffalo have devised ... these medically important molecules from losing their shape and ... help speed the development of peptide-based drugs against diseases ... are simpler than existing techniques, one of which employs ...
... (HealthDay News) -- People whose genetic make-up produces lower levels ... at increased risk for major depression, says a new study. ... down after experiencing stressful events. This study found that ... cause them to produce lower levels of NPY have stronger ...
... (HealthDay News) -- Babies who are exposed to HIV at ... levels of antibodies to diseases such as whooping cough, tetanus ... samples from 104 HIV-infected and uninfected South African women and ... of the infants at 16 weeks of age. The samples ...
... beneath the surface, a team of researchers from the ... three South Korean institutions have identified two distinct neuronal ... treat a variety of skin diseases. One pathway produces ... a side effect. The findings, published in this ...
Cached Medicine News:Health News:Male cancer survivor offspring slightly higher risk of congenital birth abnormalities 2Health News:New techniques for stapling peptides could spur development of drugs for cancer 2Health News:Study Links Brain Molecule to Risk of Major Depression 2Health News:Mom's HIV May Lower Baby's Immunity to Other Diseases 2Health News:The hitch in the drug? The itch in the drug 2
... was developed to address hematology needs ... of use, low maintenance, closed-tube sampling, ... are features expected in the modern ... fast access to results, sophisticated data ...
Inquire...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: